Phio Pharmaceuticals closed at $0.87 on Nov 4, down 3.67%, within 2.3% of its 52-week closing low. Volume of 66.6K shares was 1.03× its 20-day average (close to normal).
Split-adjusted performance: -12.5% over one month, -24.4% over six months, -53.2% over one year.
Short interest was 136.4K shares at the Oct 15 settlement, up 52.5% from the prior report (1.2% of float, 1.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PHIOPhio Pharmaceuticals | $0.8699 | −3.67% | −24.4% | — | — | — | $10.1M | |
| ASBPAspire-Lakewood Holdings | $7.31 | +0.55% | +31.0% | — | −2009.6% | — | $10.3M | Compare |
| BFRGBullfrog AI Holdings | $0.5263 | +0.59% | −25.4% | +547.6% | −636.8% | — | $9.8M | Compare |
| PTNPalatin Technologies | $6.02 | +15.33% | −68.3% | — | −1449.1% | — | $10.7M | Compare |
| RKTORocket One | $0.4422 | −4.33% | — | — | — | — | $11.0M | Compare |
| TPSTTempest Therapeutics | $0.4633 | −1.13% | −77.1% | — | — | — | $9.3M | Compare |
| CALCCalciMedica | $1.35 | −8.50% | −56.8% | — | — | — | $9.2M | Compare |
| CURXCuranex Pharmaceuticals | $5.80 | −6.30% | −17.7% | — | — | — | $9.1M | Compare |
| LSTALisata Therapeutics | $1.06 | −2.75% | −67.5% | −100.0% | — | — | $11.5M | Compare |
No recent articles focused on Phio Pharmaceuticals.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
